

**April 11, 2024**

**The Listing Department  
BSE Limited  
Phiroze Jeebhoy Towers,  
Dalal Street, Fort,  
Mumbai – 400001  
BSE Scrip Code: 543427**

**The Listing Department  
National Stock Exchange of India Limited  
Exchange Plaza, 5<sup>th</sup> Floor  
Plot No. C/1, G Block,  
Bandra - Kurla Complex  
Bandra (East), Mumbai – 400051  
NSE Symbol: MEDPLUS**

Dear Sir/Madam,

**Sub: Intimation under Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”)**

Pursuant to Regulation 30 of SEBI Listing Regulations, we hereby inform that one of the subsidiary of the Company i.e., Optival Health Solutions Private Limited has received suspension orders from Drugs and Control authorities under Drugs and Cosmetic Act, 1940 and Drugs and Cosmetics Rules, 1945 temporarily suspending the operations pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 details are provided below:

<b>Name(s) of the Authority:</b>	<b>Nature and details of the action(s) taken, initiated or order(s) passed</b>	<b>Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority</b>	<b>Details of the violation(s) / contravention(s) committed or alleged to be committed</b>	<b>Impact on financial operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible</b>
Food and Drug Administration, Mumbai	Temporary suspension of Drug License for fifteen days of a store situated at Pherozshah Ville Parle, Mumbai, Maharashtra	Order received on 10.04.2024	Under Rule 65(3), 65(2), 65(9)(A), 65(16) & 65(11)(C) under the Drug and Cosmetic Act, 1940 and Rules, 1945	Potential Revenue Loss of Rs~ 8.62 Lacs.
Food and Drug Administration, Mumbai	Temporary suspension of Drug License for fifteen days of a store situated at Old Nagardas Road-Andheri, Mumbai, Maharashtra	Order received on 10.04.2024	Under Rule 65(3)(1), 65(4)(4)(ii), 65(9)(A), 65(4)(3)(ii) & 65(16)(C) under the Drug and Cosmetic Act, 1940 and Rules, 1945	Potential Revenue Loss of Rs~ 8.37 Lacs.

The Company is reviewing the aforesaid order and evaluating the next steps in this matter.

Kindly take the same on records.

**For MedPlus Health Services Limited**

**Manoj Kumar Srivastava  
Company Secretary  
FCS 7460**